SillaJen's 'Two Research Studies' Accepted by European Society for Medical Oncology... Presentation in October

Shinilgen announced on the 24th that the presentation materials on the study results of Pexa-Vec and Libtayo combination therapy for renal cancer patients and the overview of the ‘BAL0891’ study have been selected as posters at the ‘European Society for Medical Oncology Annual Meeting 2023’ (ESMO 2023), held in Madrid, Spain from October 20 to 24.

The European Society for Medical Oncology (ESMO), along with the American Society of Clinical Oncology (ASCO) held in the first half of each year, is one of the world’s most prestigious cancer-related conferences and is held annually in rotation among major European countries in the second half of the year. Shinilgen submitted two research studies to this year’s ESMO, both of which were accepted.

The first study is the clinical research results of the combination of Pexa-Vec and Libtayo targeting renal cancer patients. Shinilgen and the global big pharma Regeneron signed a joint development agreement related to renal cancer clinical trials in 2017 and have been conducting combination clinical trials of the oncolytic virus Pexa-Vec and the immune checkpoint inhibitor Libtayo. The Phase 2 clinical trial is currently being completed, and the Clinical Study Report (CSR) is expected to be released in the second half of this year. Notably, this clinical trial includes intravenous (IV) administration of the oncolytic virus and studies on patients who relapsed after immune checkpoint inhibitor treatment in its clinical design, attracting attention from the industry.

The Phase 1 clinical trial of the mitotic checkpoint inhibitor (MCI) ‘BAL0891’, introduced from Basilea, Switzerland last year, was selected in the Trial in Progress section. ‘BAL0891’ is the first MCI-class drug that simultaneously inhibits TTK and PLK1. Currently, Phase 1 clinical trials are underway in the United States and Korea targeting metastatic solid tumors. The company explained that being selected in the Trial in Progress section at a major conference like ESMO means that although the research is not yet completed, there are high expectations for the drug and the clinical trial.

A Shinilgen official stated, “The acceptance of two research studies with different pipelines at the world’s most prestigious conference signifies that the company’s pipeline has become more robust,” and added, “We will do our utmost to enhance corporate value through the successful development of various pipelines.”

This content was produced with the assistance of AI translation services.